Hengrui Pharma(SH:600276) 智通财经网·2025-12-15 02:59Group 1 - The global anticoagulant market exceeds $20 billion, with existing anticoagulants posing additional bleeding risks while preventing thrombosis. There is room for improvement in both efficacy and safety of these drugs [1] - FXI/FXIa inhibitors are expected to become safer alternatives to current anticoagulants, as they specifically target the intrinsic coagulation pathway, potentially reducing bleeding risks while maintaining anticoagulant efficacy [1] - No FXI/FXIa inhibitors have been approved yet, but several candidates, including Novartis' abelacimab, Bayer's asundexian, and BMS/Johnson & Johnson's milvexian, are in registration clinical trials [1] Group 2 - Bayer's asundexian has shown superior efficacy in phase 3 clinical trials for secondary stroke prevention, marking it as the first FXI/FXIa inhibitor to meet key clinical endpoints [1] - FXI/FXIa inhibitors demonstrate significant safety advantages over DOACs, particularly in patients at high risk of bleeding, and are expected to challenge standard treatments in various indications [1] - FXI small nucleic acid drugs, still in early development, show promising early pharmacokinetic and pharmacodynamic data, with potential for improved patient compliance due to less frequent dosing [2]